Zusammenfassung
Bei der retroperitonealen Fibrose (RPF) handelt es sich um eine seltene chronisch entzündlich-fibrosierende Erkrankung des hinteren Bauchraumes. Sie ist gekennzeichnet durch die gutartige Vermehrung von retroperitonealem Weichteilgewebe. In ihrer typischen Lokalisation breitet sich die Fibrose symmetrisch um die Aorta aus, beginnt unterhalb der Nierenstielgefäße und reicht bis unterhalb der Aortenbifurkation. Bei ihrer Ausbreitung erreicht die Fibrose meist als erstes Organ die Ureteren, so dass eine obstruktive Uropathie mit konsekutiver Hydronephrose die häufigste Komplikation dieser Erkrankung ist.
Literatur
Adler S, Lodermeyer S et al (2008) Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology 47(10):1535–1538
Alberici F, Palmisano A et al (2013) Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis 72(9):1584–1586
Armatys SA, Mellon MJ et al (2009) Use of ileum as ureteral replacement in urological reconstruction. J Urol 181(1):177–181
Binder M, Christoph S et al (2012) Elevated serum osteopontin levels in idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 30(5):772–775
Bommel EF van, Hendriksz TR et al (2006) Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 144(2):101–106
Bommel EF van, Pelkmans LG et al (2013) Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J Intern Med 24(5):444–450
Bommel EF van, Siemes C et al (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49(5):615–625
Brandt AS, Kamper L et al (2011) Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry. J Urol 185(2):526–531
Brandt AS, Kamper L et al (2013) An aid to decision-making in therapy of retroperitoneal fibrosis: dynamic enhancement analysis of gadolinium MRI. J Clin Med Res 5(1):49–56
Burkhardt Soares S, Fehr A et al (2007) Retroperitoneal fibrosis. Aktuelle Urol 38(3):221–231
Burn PR, Singh S et al (2002) Role of gadolinium-enhanced magnetic resonance imaging in retroperitoneal fibrosis. Can Assoc Radiol J 53(3):168–170
Caiafa RO, Vinuesa AS et al (2013) Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up. Radiographics Rev Publ Radiol Soc N Am Inc 33(2):535–552
Catanoso MG, Spaggiari L et al (2012) Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 30(5):776–778
Duchene DA, Winfield HN et al (2007) Multi-institutional survey of laparoscopic ureterolysis for retroperitoneal fibrosis. Urology 69(6):1017–1021
Fry AC, Singh S et al (2008) Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Nephron Clin Pract 108(3):c213–c220
Heidenreich A, Derakhshani P et al (2000) Treatment outcomes in primary and secondary retroperitoneal fibrosis. Urologe A 39(2):141–148
Ilie CP, Pemberton RJ et al (2006) Idiopathic retroperitoneal fibrosis: the case for nonsurgical treatment. BJU Int 98(1):137–140
Kamper L, Brandt AS et al (2011) MR evaluation of retroperitoneal fibrosis. RoFo: Fortschr Geb Rontgenstr Nuklearmed 183(8):721–726
Kardar AH, Kattan S et al (2002) Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol 168(2):550–555
Khosroshahi A, Carruthers MN et al (2013) Rethinking Ormond’s disease: „idiopathic“ retroperitoneal fibrosis in the era of IgG4-related disease. Medicine 92(2):82–91
Magrey MN, Husni ME et al (2009) Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum 61(5):674–679
Marcolongo R, Tavolini IM et al (2004) Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 116(3):194–197
Martorana D, Marquez A et al (2018) A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. J Allergy Clin Immunol 142(5):1662–1665
Martorana D, Vaglio A et al (2006) Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. Arthritis Rheum 55(1):126–130
Marzano A, Trapani A et al (2001) Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis 60(4):427–428
Moriconi D, Giannese D et al (2019) Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis. Clin Exp Nephrol 23(9):1147–1153
Moroni G, Castellani M et al (2012) The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 39(10):1635–1642
Mufarrij PW, Stifelman MD (2006) Robotic ureterolysis, retroperitoneal biopsy, and omental wrap for the treatment of ureteral obstruction due to idiopathic retroperitoneal fibrosis. Rev Urol 8(4):226–230
Pelkmans LG, Aarnoudse AJ et al (2012) Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant Official Publ Eur Dial Transplant Assoc Eur Renal Assoc 27(7):2819–2825
Pelkmans LG, Hendriksz TR et al (2017) Elevated serum IgG4 levels in diagnosis and treatment response in patients with idiopathic retroperitoneal fibrosis. Clin Rheumatol 36(4):903–912
Raffiotta F, da Silva Escoli R et al (2019) Idiopathic retroperitoneal fibrosis: long-term risk and predictors of relapse. Am J Kidney Dis 74(6):742–750
Scheel PJ Jr, Feeley N (2009) Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine 88(4):202–207
Scheel PJ Jr, Piccini J et al (2007) Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol 178(1):140–143. discussion 143–144
Scheel PJ Jr, Sozio SM et al (2012) Medical management of retroperitoneal fibrosis. Trans Am Clin Climatol Assoc 123:283–290. discussion 290–281
Stifelman MD, Shah O et al (2008) Minimally invasive management of retroperitoneal fibrosis. Urology 71(2):201–204
Swartz RD (2009) Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment. Am J Kidney Dis 54(3):546–553
Swartz RD, Lake AM et al (2008) Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil. Clin Nephrol 69(4):260–268
Treglia G, Mattoli MV et al (2013) Emerging role of Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review. Rheumatol Int 33(3):549–555
Uibu T, Oksa P et al (2004) Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet 363(9419):1422–1426
Vaglio A (2009) Retroperitoneal fibrosis: new insights into clinical presentation and diagnosis. Medicine 88(4):208–210
Vaglio A, Buzio C (2005) Chronic periaortitis: a spectrum of diseases. Curr Opin Rheumatol 17(1):34–40
Vaglio A, Greco P et al (2006a) Autoimmune aspects of chronic periaortitis. Autoimmun Rev 5(7):458–464
Vaglio A, Palmisano A et al (2011) Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 378(9788):338–346
Vaglio A, Salvarani C et al (2006b) Retroperitoneal fibrosis. Lancet 367(9506):241–251
Vega J, Goecke H et al (2009) Treatment of idiopathic retroperitoneal fibrosis with colchicine and steroids: a case series. Am J Kidney Dis Off J Natl Kidney Found 53(4):628–637
Warnatz K, Keskin AG et al (2005) Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 64(6):828–833
Zen Y, Onodera M et al (2009) Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 33(12):1833–1839
Zhao J, Li J et al (2019) Long-term outcomes and predictors of a large cohort of idiopathic retroperitoneal fibrosis patients: a retrospective study. Scand J Rheumatol 48(3):239–245
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this entry
Cite this entry
Brandt, A.S., Goedde, D., Kamper, L., Haage, P., Störkel, S., Roth, S. (2022). Retroperitoneale Fibrose (Morbus Ormond). In: Michel, M.S., Thüroff, J.W., Janetschek, G., Wirth, M.P. (eds) Die Urologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41168-7_112-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-41168-7_112-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-41168-7
Online ISBN: 978-3-642-41168-7
eBook Packages: Springer Referenz Medizin
Publish with us
Chapter history
-
Latest
Retroperitoneale Fibrose (Morbus Ormond)- Published:
- 02 February 2022
DOI: https://doi.org/10.1007/978-3-642-41168-7_112-2
-
Original
Retroperitoneale Fibrose (Morbus Ormond)- Published:
- 19 February 2015
DOI: https://doi.org/10.1007/978-3-642-41168-7_112-1